Tanios Bekaii-Saab, MD, FACP

Articles

Dr Bekaii-Saab on the Role of Liquid and Tissue Biopsies for Newly Diagnosed GI Cancers

November 4th 2024

Tanios Bekaii-Saab, MD, FACP, discusses the role of liquid and tissue biopsies in newly diagnosed gastrointestinal cancers.

Dr Bekaii-Saab on Frontline Treatment Considerations for BRCA1/2+ Pancreatic Cancer

October 25th 2024

Tanios Bekaii-Saab, MD, FACP, discusses the evolving treatment paradigm for BRCA1- and BRCA2-positive pancreatic cancer in the first-line setting.

Dr Bekaii-Saab on the Final Analysis of MOUNTAINEER in HER2+ CRC

August 8th 2024

Tanios Bekaii-Saab, MD, FACP, discusses final results from the MOUNTAINEER trial in HER2+ metastatic colorectal cancer.

Dr Bekaii-Saab on the Benefits of Multidisciplinary Conferences in GI Cancer Care

August 7th 2024

Tanios Bekaii-Saab, MD, FACP, discusses the benefits of multidisciplinary conferences within the gastrointestinal cancer treatment field.

Dr Bekaii-Saab on the Ongoing Development of Targeted Therapies in GI Malignancies

July 25th 2024

Tanios Bekaii-Saab, MD, FACP, discusses next-generation sequencing and the development of RAS-targeted therapies in gastrointestinal cancers.

Dr Bekaii-Saab on Treatment Evolutions in KRAS G12C–Mutant and HER2-Overexpressing CRC

October 18th 2023

Tanios Bekaii-Saab, MD, FACP, discusses the evolution of treatment for patients with KRAS G12C–mutant and HER2-overexpressing colorectal cancer.

Future Perspectives on HER2+ Metastatic Colorectal Cancer

July 28th 2023

Tanios S. Bekaii-Saab, MD, offers closing thoughts on the unmet needs and future of HER2+ metastatic colorectal cancer treatment.

DESTINY-CRC02: Trastuzumab Deruxtecan in HER2+ Metastatic Colorectal Cancer

July 21st 2023

An overview of the DESTINY-CRC02 study, which looked at trastuzumab deruxtecan in patients with HER2+ metastatic colorectal cancer.

Evolving Treatment Landscape in Metastatic Colorectal Cancer

July 21st 2023

Tanios S. Bekaii-Saab, MD, discusses recent clinical trials and provides insights on the evolving metastatic colorectal cancer treatment landscape.

HER2 as a Biomarker in Metastatic Colorectal Cancer

July 14th 2023

An expert on colorectal cancer discusses the relationship between HER2 status and treatment selection and response.

Overview of Metastatic Colorectal Cancer: Presentation and Molecular Testing

July 14th 2023

Tanios S. Bekaii-Saab, MD, gives an overview of the presentation trends and molecular testing practices for metastatic colorectal cancer.

The Future of the Metastatic Colorectal Cancer Treatment Landscape

March 2nd 2023

Dr Tanios S. Bekaii-Saab closes the discussion with key unmet needs in the mCRC treatment landscape.

Emerging Treatment Options for Patients with HER2+ Metastatic Colorectal Cancer

February 23rd 2023

Discussion centered around emerging treatment options for patients with HER2+ mCRC, including trastuzumab deruxtucan.

MOUNTAINEER-03 Clinical Trial Study Design and Implications

February 23rd 2023

Clinical insights regarding the design, patient population, and overall aims of the ongoing phase 3 clinical trial MOUNTAINEER-03.

Clinical Trial Review: MOUNTAINEER

February 16th 2023

An expert in gastrointestinal cancers reviews outcomes from the MOUNTAINEER clinical trial, focusing on concordance analysis data for HER2 testing as well as the efficacy of tucatinib and trastuzumab.

An Introduction to Biomarker Testing in Metastatic Colorectal Cancer

February 16th 2023

Tanios S. Bekaii-Saab, MD, FACP introduces the metastatic colorectal cancer (mCRC) treatment landscape and the emphasizes importance of biomarker testing in patients with mCRC.

Promising Early Data from GI Malignancy Trials

August 3rd 2022

Tanios S. Bekaii-Saab, MD shares his perspective on exciting breakthroughs in GI malignancy research and treatment, focusing on HER2, BRAF V600E, and KRAS g12c.

MOUNTAINEER Trial: Rationale, Results and Clinical Implications

August 3rd 2022

Subject matter expert discusses the impetus for and data from the MOUNTAINEER trial, touching on patient populations, study design, and key efficacy and safety endpoints.

HER2 as a Potential Drug Target and its Prevalence in GI Malignancies

August 3rd 2022

An experienced oncologist discusses the role of HER2 in GI malignancies and the applicability of the existing body of research concerning HER2 in breast cancer.

Recent Advancements and Current Areas of Focus in the Treatment of mCRC

August 3rd 2022

Tanios S. Bekaii-Saab, MD describes recent progress in the metastatic colorectal cancer treatment landscape and raises key questions concerning the future of the field.